Enrichment of stem cell-derived pancreatic beta-like cells and controlled graft size through pharmacological removal of proliferating cells
Stem Cell Reports · 2023
DOI: 10.1016/j.stemcr.2023.05.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell Reports, 2023. Verfasst von Ali H Shilleh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barbara-Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Pancreas, Insulin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIAMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Transplantation of limited human cadaveric islets into type 1 diabetic patients results in ∼35 months of insulin independence. Direct differentiation of stem cell-derived insulin-producing beta-like cells (sBCs) that can reverse diabetes in animal models effectively removes this shortage constraint, but uncontrolled graft growth remains a concern. Current protocols do not generate pure sBCs, but consist of only 20%-50% insulin-expressing cells with additional cell types present, some of which are proliferative. Here, we show the selective ablation of proliferative cells marked by SOX9 by simple pharmacological treatment in vitro. This treatment concomitantly enriches for sBCs by ∼1.7-fold. Treated sBC clusters show improved function in vitro and in vivo transplantation controls graft size. Overall, our study provides a convenient and effective approach to enrich for sBCs while minimizing the presence of unwanted proliferative cells and thus has important implications for current cell therapy approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara-Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Barbara-Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: holger.russ@ufl.edu.
Förderung
- NIDDK NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- Juvenile Diabetes Research Foundation United States of America
- HIRN
Zitieren
APA
Shilleh, A. H., Beard, S., & Russ, H. A. (2023). Enrichment of stem cell-derived pancreatic beta-like cells and controlled graft size through pharmacological removal of proliferating cells. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2023.05.010
Vancouver
Shilleh AH, Beard S, Russ HA. Enrichment of stem cell-derived pancreatic beta-like cells and controlled graft size through pharmacological removal of proliferating cells. Stem Cell Reports. 2023. doi:10.1016/j.stemcr.2023.05.010
BibTeX
@article{Shilleh2023,
author = {Shilleh, Ali H and Beard, Scott and Russ, Holger A},
title = {Enrichment of stem cell-derived pancreatic beta-like cells and controlled graft size through pharmacological removal of proliferating cells},
journal = {Stem Cell Reports},
year = {2023},
doi = {10.1016/j.stemcr.2023.05.010}
}
EUVIMED